News
Remiges led the Series A round of finance for Phost'in Therapeutics in France
04/20/2020
Phost’in Therapeutics (Montpellier, France), a biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors, today announced that it has successfully secured a €10.3 million Series A round, from an international syndicate of Life Science and Innovation Investors led by Remiges Ventures and completed by ANRI and Irdi Soridec Gestion. The Series A funding will be used to advance the clinical development of Phost’in’s main program, PhOx430, and to enhance capacity of its discovery platform.
For more detailed information please visit the above web page